"Trial Shows Vet Drug Monepantel Slows ALS Disease Progression"
Daily treatment with the veterinary drug monepantel was found to reduce the rate of disease progression by up to 58% in people with ALS or MND, with generally safe and well-tolerated oral therapy. The completed MEND trial in Australia showed promising preliminary efficacy, leading to plans for a Phase 2/3 study to start later this year. Monepantel, known for deworming in veterinary medicine, may activate a pathway to clear toxic proteins contributing to disease progression, potentially extending survival by 13.5 to 56.5 months.